Stock listing
OTC:ARYX Aryx Therapeutics Inc Stock
Follow Aryx Therapeutics Inc into a list and get an email when it puts out news.

- Ticker
- OTC:ARYX
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Events
| Quarter | Results |
|---|---|
| Quarter to Sep 30, 2024 | Nov 18, 2024 |
| Quarter to Jun 30, 2024 | Aug 12, 2024 |
| Quarter to Mar 31, 2024 | May 16, 2024 |
| Quarter to Dec 31, 2023 | Mar 25, 2024 |
| Quarter to Sep 30, 2023 | Nov 13, 2023 |
| Quarter to Jun 30, 2023 | Aug 14, 2023 |
| Quarter to Mar 31, 2023 | May 11, 2023 |
| Quarter to Dec 31, 2022 | Mar 27, 2023 |
| Quarter to Sep 30, 2022 | Nov 14, 2022 |
| Quarter to Jun 30, 2022 | Aug 15, 2022 |
All 16 quarters
| Quarter | Results |
|---|---|
| Quarter to Mar 31, 2022 | May 12, 2022 |
| Quarter to Dec 31, 2021 | Mar 28, 2022 |
| Quarter to Sep 30, 2021 | Nov 15, 2021 |
| Quarter to Jun 30, 2021 | Aug 16, 2021 |
| Quarter to Mar 31, 2021 | May 13, 2021 |
| Quarter to Dec 31, 2020 | Mar 29, 2021 |
Financials
Annual, in USD
Income statement
| Line | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 19.7M | 4.16M | 4.74M | |||
| Cost of revenue | 0 | 232.0K | 262.0K | 2.12M | 27.4M | ||
| Gross profit | 0 | 19.5M | 3.90M | 2.62M | |||
| Research and development | 21.0M | 40.1M | 25.0M | 24.0M | 22.5M | 10.7M | |
| Selling, general and administrative | 10.2M | 10.1M | 7.70M | 6.94M | |||
| Operating income | -31.2M | -30.4M | -28.8M | -28.3M | -28.2M | -20.8M | -14.1M |
| Depreciation and amortization | 1.08M | 1.46M | 1.24M | 920.0K | 982.0K | ||
| EBITDA | -30.2M | -29.0M | -27.6M | -27.4M | -27.2M | ||
| Interest expense | 2.01M | 1.93M | 1.35M | 1.32M | 671.0K | 58.0K | |
| Income before tax | -33.2M | -31.2M | -27.6M | -27.3M | |||
| Income tax | 849.0K | 801.0K | -1.24M | -960.0K | -205.0K | 20.8M | 14.0M |
| Net income | -33.2M | -31.2M | -27.6M | -27.3M | -28.0M | -20.8M | -14.0M |
| Earnings per share, basic | -1.21 | -1.65 | -2.93 | -26.84 | -30.73 | -24.27 | -16.67 |
Balance sheet
| Line | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.41M | 36.0M | 55.5M | 18.7M | 12.5M | ||
| Short-term investments | 353.0K | 8.59M | 7.64M | 31.6M | 13.9M | ||
| Receivables | 45.0K | ||||||
| Inventory | 0 | 0 | 0 | 0 | |||
| Current assets | 8.81M | 45.9M | 64.9M | 51.4M | 27.7M | ||
| Property, plant and equipment | 2.26M | 3.20M | 3.65M | 4.17M | 4.14M | ||
| Goodwill | 0 | 0 | 0 | 0 | |||
| Total assets | 12.4M | 51.1M | 69.6M | 56.8M | 33.3M | 8.85M | |
| Accounts payable | 685.0K | 2.45M | 1.37M | 691.0K | 656.0K | ||
| Current liabilities | 8.68M | 11.0M | 13.5M | 11.5M | 7.75M | ||
| Long-term debt | 5.28M | 10.2M | 3.44M | 6.68M | 8.92M | ||
| Total debt | 11.8M | 14.7M | 6.98M | 9.88M | 11.2M | ||
| Total liabilities | 15.3M | 23.7M | 34.3M | 150.5M | 100.4M | ||
| Shareholders' equity | -2.92M | 27.4M | 35.3M | -93.7M | -67.1M | -18.9M | |
| Shares outstanding | 27.4M | 19.0M | 9.41M | 1.02M | 910.0K | 858.0K | 838.0K |
Cash flow
| Line | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 |
|---|---|---|---|---|---|
| Cash from operations | -35.0M | -45.2M | -27.7M | -4.21M | -22.4M |
| Capital spending | -141.0K | -644.0K | -499.0K | -962.0K | -3.85M |
| Free cash flow | -35.1M | -45.9M | -28.2M | -5.17M | -26.3M |
| Cash from investing | 8.41M | -2.41M | 23.4M | -18.5M | 9.53M |
| Cash from financing | -2.04M | 28.2M | 41.2M | 28.9M | 11.2M |
| Dividends paid | 0 | 0 | 0 | 0 | |
| Share buybacks | -92.0K | 0 | 0 | 0 | |
| Change in cash | -28.6M | -19.5M | 36.8M | 6.21M | -1.73M |
Cap table
Built by 6ix from Aryx Therapeutics Inc’s releases
- Common shares
- 33,461,975
- Fully diluted
- 33,461,975
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 33,461,975 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 33,461,975 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Samuel D Isaly Other companies: Synlogic Inc (Director · Aug 28, 2017 – Aug 28, 2017 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – Jul 24, 2017 · Past); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Mar 15, 2017 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Dec 30, 2016 · Past); Roka Bioscience Inc (Director · Sep 21, 2016 – Sep 21, 2016 · Past); Loxo Oncology Inc (Director · Aug 10, 2016 – Dec 8, 2017 · Past); Audentes Therapeutics Inc (Director · Jul 19, 2016 – Jul 19, 2016 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Corvus Pharmaceuticals, Inc. (Director · May 18, 2016 – Jun 23, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 11, 2016 – May 11, 2016 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Mar 27, 2017 · Past); Otonomy Inc (Director · Nov 17, 2015 – Nov 25, 2015 · Past); Dimension Therapeutics (Director · Oct 27, 2015 – Oct 27, 2015 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Jul 21, 2015 · Past); Palvella Therapeutics, Inc. (Director · Jun 29, 2015 – Jul 6, 2015 · Past); Glaukos Corporation (Director · Jun 24, 2015 – Aug 31, 2017 · Past); Intercept Pharmaceuticals Inc (Director · Apr 9, 2013 – Jul 17, 2015 · Past); Supernus Pharmaceuticals, Inc. (Director · May 4, 2012 – May 4, 2012 · Past); Anthera Pharmaceuticals Inc (Director · May 9, 2011 – Jan 30, 2013 · Past); Amarin Corporation plc (Director · Jan 1, 2011 – Sep 4, 2012 · Past); NxStage Medical Inc (Director · Jul 23, 2008 – Dec 9, 2010 · Past); Albireo Pharma Inc (Director · Feb 12, 2008 – Jun 9, 2009 · Past); Insulet Corporation (Director · May 14, 2007 – May 14, 2007 · Past); Volcano Corp (Director · Jun 14, 2006 – Jun 20, 2006 · Past); Given Imaging Ltd (Director · May 24, 2006 – May 24, 2006 · Past); Avanir Pharmaceuticals Inc (Director · Feb 13, 2006 – May 31, 2006 · Past) | Director · Nov 7, 2007 – Nov 13, 2007 · Past |
| Lars G. Ekman Other companies: Prothena Corporation plc (Chair Emeritus · Since at least Dec 20, 2012); Ultragenyx Pharmaceutical Inc. (Director · Mar 17, 2016 – Jun 24, 2022 · Past); Spark Therapeutics Inc (Director · Jan 29, 2015 – Dec 17, 2019 · Past); Ocera Therapeutics Inc (Director · Jul 15, 2013 – Jun 11, 2014 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Jun 27, 2022 · Past); InterMune Inc (Director · May 10, 2010 – Sep 29, 2014 · Past) | Director · Apr 30, 2010 – Apr 30, 2010 · Past |
| Keith R. Leonard Other companies: Arcutis Biotherapeutics, Inc. (Director · Since at least Sep 2, 2021); Intuitive Surgical, Inc. (Chairman, Unity Biotechnology, Inc · Since at least Jan 28, 2016); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 21, 2024 · Past); Kythera Biopharmaceuticals Inc (President & CEO, Director · Jan 29, 2012 – Oct 1, 2015 · Past); Affymax Inc (Director · Dec 6, 2007 – Jun 13, 2012 · Past) | Director · Nov 7, 2007 – Apr 30, 2010 · Past |
| John Varian Other companies: SELLAS Life Sciences Group, Inc. (Director · Since at least Dec 29, 2017); Acorda Therapeutics Inc (Director · Jan 1, 2022 – Jun 22, 2023 · Past); Egalet Corporation (Director · Jun 6, 2018 – Jan 31, 2019 · Past); Aravive Inc (Director · Mar 20, 2014 – Dec 20, 2017 · Past) | COO & CFO · Nov 7, 2007 – Feb 25, 2010 · Past |
| Paul Goddard Other companies: Corium International Inc (Director · Sep 16, 2014 – Nov 27, 2018 · Past); Heron Therapeutics, Inc. (Director · Apr 19, 2006 – May 26, 2010 · Past); Adolor Corp (Director · Apr 13, 2006 – Dec 7, 2011 · Past); Onyx Pharmaceuticals Inc (Director · Feb 7, 2006 – Oct 1, 2013 · Past) | Chairman & CEO, Director · Nov 7, 2007 – Feb 25, 2010 · Past |
| David Nagler Other companies: Audentes Therapeutics Inc (SVP, HR & Corp. Affairs · Jul 19, 2016 – Jun 20, 2018 · Past) | V.P.,Corp. Affairs & Sect. · Nov 7, 2007 – Feb 25, 2010 · Past |
| Jason Barker Other companies: Arcus Biosciences, Inc. (See Remarks · Oct 1, 2019 – Jun 4, 2020 · Past) | Sr.Dir.& Principal Acctg. Off. · Nov 7, 2007 – Feb 17, 2010 · Past |
| Nicholas J Simon III Other companies: Barrier Therapeutics Inc (Director · Jun 6, 2007 – Jun 6, 2007 · Past) | Director · Nov 7, 2007 – Sep 30, 2010 · Past |
| Pascal Druzgala | Sr. V.P. & Chief Scien.Off. · Nov 7, 2007 – Feb 25, 2010 · Past |
| Peter G Milner | Pres., Research & Dev., Director · Nov 7, 2007 – Feb 25, 2010 · Past |
Log in to ask 6ix AI your own questions about Aryx Therapeutics Inc.